Milrinone Lactate In Dextrose Injection, Solution
NDC Package 68083-411-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Milrinone Lactate In Dextrose (milrinone lactate) injection is a medication used for the short-term treatment of heart failure. This formulation utilizes a injection, solution delivery system. Marketed by Gland Pharma Limited, this product is identified by NDC 68083-411 and is authorized under FDA application ANDA213585.

Identification & Billing

NDC Package Code
68083-411-10
Package Description
10 CARTON in 1 CARTON / 1 BAG in 1 CARTON (68083-411-01) / 200 mL in 1 BAG
Product Code
68083-411
11-Digit Billing Format
68083041110
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Milrinone Lactate In Dextrose
Non-Proprietary Name
Milrinone Lactate
Substance Name
Milrinone Lactate
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
MILRINONE LACTATE .2 mg/mL
Pharmacologic Class
Usage Information
This medication is used for the short-term treatment of heart failure. It works by making your heart beat stronger and by relaxing certain blood vessels so that the amount of blood that is pumped from the heart is increased. This effect may help with symptoms of heart failure (such as shortness of breath, tiredness).

Regulatory & Marketing

Labeler Name
Gland Pharma Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA213585
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-16-2020
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68083-411-10 identifies a specific commercial package of 10 carton in 1 carton / 1 bag in 1 carton (68083-411-01) / 200 ml in 1 bag of Milrinone Lactate In Dextrose, a human prescription drug labeled by Gland Pharma Limited. This injection, solution is formulated for intravenous use and contains milrinone lactate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gland Pharma Limited on July 16, 2020. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used for the short-term treatment of heart failure. It works by making your heart beat stronger and by relaxing certain blood vessels so that the amount of blood that is pumped from the heart is increased. This effect may help with symptoms of heart failure (such as shortness of breath, tiredness).

How is this Gland Pharma Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68083041110. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68083-411-10
11-Digit CMS (5-4-2)
68083-0411-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.